Hansa Biopharma AB - Company Profile
Powered by 
All the data and insights you need on Hansa Biopharma AB in one report.
$295
- Save hours of research time and resources with
our up-to-date Hansa Biopharma AB Strategy Report
- Understand Hansa Biopharma AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Hansa Biopharma AB (Hansa Biopharma) focuses on harnessing its enzyme technology platform and develops novel immunomodulatory enzymes for transplant rejection and treatment and prevention of rare, cancer and severe autoimmune conditions. It develops novel drugs to advance the treatment of rare, severe and life-threatening IgG mediated conditions in transplantation and autoimmunity.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Hansa Biopharma focuses on harnessing its enzyme technology platform and develops novel immunomodulatory enzymes for transplant rejection and treatment and prevention of rare, cancer and severe autoimmune conditions. In addition to its ongoing clinical programs, the company is conducting preclinical research to explore the potential of its technology platform as a pre-treatment in gene therapy. The company is also working on developing its next-generation enzyme for repeat dosing. In FY2022, the company incurred R&D expenses of SEK339.2 million.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer